All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 6th European CAR T-Cell Meeting, the Lymphoma Hub was pleased to speak to the president of EBMT, Anna Sureda, Catalan Institute of Oncology, Barcelona, ES. We asked, What are the strategies to manage toxicities with CAR T-cell therapies?
What are the strategies to manage toxicities with CAR T-cell therapies?
Firstly, Sureda highlights that while CAR T-cell therapies have made significant improvements in the treatment of hematologic malignancies, they are associated with early and long-term toxicities that need to be managed. The two most important early toxicities are cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. The management approach includes the earlier use of tocilizumab for cytokine release syndrome and pre-emptive corticosteroids for immune effector cell-associated neurotoxicity syndrome, taking certain risk factors into account, such as tumor burden, age, and performance status.
Sureda then mentions other clinical toxicities associated with CAR T-cell therapies, such as hematologic toxicities, cytopenias, and the ongoing measures to manage these. She concludes by discussing the recent development of secondary malignancies post CAR T-cell therapy including myelodysplastic syndromes and acute myeloid leukemia; investigations are ongoing to further understand the profile of this toxicity.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox